Literature DB >> 22054801

MDCT necrosis quantification in the assessment of hepatocellular carcinoma response to yttrium 90 radioembolization therapy: comparison of two-dimensional and volumetric techniques.

Mauricio Stanzione Galizia1, Hüseyin Gürkan Töre, Hamid Chalian, Robert McCarthy, Riad Salem, Vahid Yaghmai.   

Abstract

RATIONALE AND
OBJECTIVES: The purpose of this study is to evaluate the reproducibility and agreement of tumor necrosis quantification performed by two-dimensional and volumetric methods in a cohort of patients with hepatocellular carcinoma (HCC) treated with yttrium-90 ((90)Y) radioembolization.
MATERIALS AND METHODS: Twenty-nine consecutive patients (21 men, 8 women; mean age 66.6 years; age range, 44-90 years) with HCC treated with (90)Y radioembolization that underwent liver multidetector computed tomography (MDCT) were included. Two independent radiologists evaluated the necrosis proportion of the lesions with two-dimensional (2D) measurements according to the European Association for the Study of the Liver guidelines, and with a volumetric method using a voxel-by-voxel analysis. Interobserver reproducibility for each method was assessed by using within-subject coefficients of variation (WSCV), intraclass correlation coefficients (ICC), and Lin's concordance correlation coefficients (LCC). Agreement between both methods was assessed by using the Bland-Altman plot and the paired t-test.
RESULTS: The volumetric method was more reproducible (WSCV = 27.8%; ICC = 0.914; LCC = 0.909) than the 2D (WSCV = 43.8%; ICC = 0.723; LCC = 0.841). There was a significant difference in the mean calculated necrosis proportions based on 2D and volumetric methods (P = .0129).
CONCLUSION: Voxel-by-voxel quantification of HCC necrosis is a more reproducible method than 2D analysis.
Copyright © 2012 AUR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22054801     DOI: 10.1016/j.acra.2011.09.005

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  12 in total

1.  A predictive model for distinguishing radiation necrosis from tumour progression after gamma knife radiosurgery based on radiomic features from MR images.

Authors:  Zijian Zhang; Jinzhong Yang; Angela Ho; Wen Jiang; Jennifer Logan; Xin Wang; Paul D Brown; Susan L McGovern; Nandita Guha-Thakurta; Sherise D Ferguson; Xenia Fave; Lifei Zhang; Dennis Mackin; Laurence E Court; Jing Li
Journal:  Eur Radiol       Date:  2017-11-24       Impact factor: 5.315

Review 2.  Assessment of clinical and radiological response to sorafenib in hepatocellular carcinoma patients.

Authors:  Rodolfo Sacco; Valeria Mismas; Antonio Romano; Marco Bertini; Michele Bertoni; Graziana Federici; Salvatore Metrangolo; Giuseppe Parisi; Emanuele Tumino; Giampaolo Bresci; Luca Giacomelli; Sara Marceglia; Irene Bargellini
Journal:  World J Hepatol       Date:  2015-01-27

3.  Interreader and inter-test agreement in assessing treatment response following transarterial embolization for hepatocellular carcinoma.

Authors:  Olivio F Donati; Richard Kinh Gian Do; Andreas M Hötker; Seth S Katz; Junting Zheng; Chaya S Moskowitz; Christopher Beattie; Karen T Brown
Journal:  Eur Radiol       Date:  2015-04-08       Impact factor: 5.315

Review 4.  Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm.

Authors:  Ania Kielar; Kathryn J Fowler; Sara Lewis; Vahid Yaghmai; Frank H Miller; Hooman Yarmohammadi; Charles Kim; Victoria Chernyak; Takeshi Yokoo; Jeffrey Meyer; Isabel Newton; Richard K Do
Journal:  Abdom Radiol (NY)       Date:  2018-01

5.  Interobserver agreement of semi-automated and manual measurements of functional MRI metrics of treatment response in hepatocellular carcinoma.

Authors:  David Bonekamp; Susanne Bonekamp; Vivek Gowdra Halappa; Jean-Francois H Geschwind; John Eng; Celia Pamela Corona-Villalobos; Timothy M Pawlik; Ihab R Kamel
Journal:  Eur J Radiol       Date:  2013-12-03       Impact factor: 3.528

Review 6.  Transarterial radioembolization for hepatocellular carcinoma: An update and perspectives.

Authors:  Rodolfo Sacco; Valeria Mismas; Sara Marceglia; Antonio Romano; Luca Giacomelli; Marco Bertini; Graziana Federici; Salvatore Metrangolo; Giuseppe Parisi; Emanuele Tumino; Giampaolo Bresci; Ambra Corti; Manuel Tredici; Michele Piccinno; Luigi Giorgi; Carlo Bartolozzi; Irene Bargellini
Journal:  World J Gastroenterol       Date:  2015-06-07       Impact factor: 5.742

7.  Aortic Volumetry at Contrast-Enhanced Magnetic Resonance Angiography: Feasibility as a Sensitive Method for Monitoring Bicuspid Aortic Valve Aortopathy.

Authors:  Brian Trinh; Iram Dubin; Ozair Rahman; Marcos P Ferreira Botelho; Nicholas Naro; James C Carr; Jeremy D Collins; Alex J Barker
Journal:  Invest Radiol       Date:  2017-04       Impact factor: 6.016

8.  Volumetric Analysis of Hepatocellular Carcinoma After Transarterial Chemoembolization and its Impact on Overall Survival.

Authors:  Monika Hajkova; Tomas Andrasina; Petra Ovesna; Tomas Rohan; Marek Dostal; Vlastimil Valek; Lenka Ostrizkova; Stepan Tucek; Jiri Sedo; Igor Kiss
Journal:  In Vivo       Date:  2022 Sep-Oct       Impact factor: 2.406

9.  Quantitative and volumetric European Association for the Study of the Liver and Response Evaluation Criteria in Solid Tumors measurements: feasibility of a semiautomated software method to assess tumor response after transcatheter arterial chemoembolization.

Authors:  MingDe Lin; Olivier Pellerin; Nikhil Bhagat; Pramod P Rao; Romaric Loffroy; Roberto Ardon; Benoit Mory; Diane K Reyes; Jean-François Geschwind
Journal:  J Vasc Interv Radiol       Date:  2012-12       Impact factor: 3.464

10.  Volumetric assessment of tumour response using functional MR imaging in patients with hepatocellular carcinoma treated with a combination of doxorubicin-eluting beads and sorafenib.

Authors:  Celia Pamela Corona-Villalobos; Vivek Gowdra Halappa; Jean-Francois H Geschwind; Susanne Bonekamp; Diane Reyes; David Cosgrove; Timothy M Pawlik; Ihab R Kamel
Journal:  Eur Radiol       Date:  2014-09-17       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.